Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Price Negotiation Surfaces Again? IMAC Proposal Needs Close Read

This article was originally published in The Pink Sheet Daily

Executive Summary

The Obama administration's proposal to establish an executive branch advisory council on Medicare payment issues may raise the threat of government negotiations for Medicare Part D drug prices.

You may also be interested in...



Medicare Commission A Key Element Of Health Care Reform Legislation, Administration Insists

During a Nov. 25 briefing, White House officials reinforced the administration's support for an advisory panel focused on reining in Medicare costs on an ongoing basis and in a way that minimizes the political fallout from those cuts.

Medicare Commission A Key Element Of Health Care Reform Legislation, Administration Insists

During a Nov. 25 briefing, White House officials reinforced the administration's support for an advisory panel focused on reining in Medicare costs on an ongoing basis and in a way that minimizes the political fallout from those cuts.

Dollars For Donuts: PhRMA's $80 Bil. Coup In Health Care Reform

PhRMA's commitment to contribute $80 billion toward health systems savings over the next 10 years looks like an important tactical win for the brand name industry entering the critical phase of the health reform debate

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel